<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828463</url>
  </required_header>
  <id_info>
    <org_study_id>UoL000928</org_study_id>
    <nct_id>NCT01828463</nct_id>
  </id_info>
  <brief_title>Dose Response Study of Nitisinone in Alkaptonuria</brief_title>
  <acronym>SONIA1</acronym>
  <official_title>An International, Multicentre, Randomised, Open-label, No-treatment Controlled, Parallel-group, Dose-response Study to Investigate the Effect of Once Daily Nitisinone on 24-hour Urinary Homogentisic Acid Excretion in Patients With Alkaptonuria After 4 Weeks Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Liverpool and Broadgreen University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SONIA 1 is an international, multicentre, randomised, open-label, no-treatment controlled,
      parallel group, dose-response study to investigate the effect of once daily nitisinone on
      24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4-weeks
      treatment. They study will identify the optimal dose to decrease urine homogentisic acid to
      near normal levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose of nitisinone that decreases urinary homogentisic acid to near normal</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparrator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitisinone 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitisinone 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitisinone 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventional</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitisinone 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>doses 1, 2, 4 &amp; 8 mg plus no treatment arm</description>
    <arm_group_label>Nitisinone 1mg</arm_group_label>
    <arm_group_label>Nitisinone 2mg</arm_group_label>
    <arm_group_label>Nitisinone 4mg</arm_group_label>
    <arm_group_label>Nitisinone 8mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        A subject must fulfil the following criteria in order to be included in the study:

          1. Diagnosis of alkaptonuria verified by documented elevated urinary homogentisic acid
             excretion.

          2. Age â‰¥18 years.

          3. Willing and able to visit the investigational site for study visits.

          4. Signed written informed consent obtained.

        Exclusion criteria

        The presence of any of the following will exclude a subject from inclusion in the study:

          1. Non-alkaptonuria causes of ochronosis.

          2. Currently pregnant or lactating.

          3. Known allergy to nitisinone or any of the constituents of the investigational product.

          4. Use of a protein-restricted diet

          5. Dietary habits or use of homeopathic therapies that interfere with tyrosine
             catabolism.

          6. Current keratopathy, contact lens use or uncontrolled glaucoma.

          7. Current malignancy.

          8. Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95
             diastolic).

          9. Electrocardiogram changes indicative of myocardial infarction, arrhythmia,
             tachycardia, bradycardia, left bundle branch block.

         10. Chest radiographic abnormalities, including an infiltrative, mass, congestive heart
             failure, embolism, atelectasis.

         11. Serum potassium &lt; 3.0 mmol/L.

         12. eGFR &lt; 60 mL/min.

         13. Any hepatic enzymes greater than 3 x upper limit of normal.

         14. Haemoglobin &lt; 10.0 g/dL.

         15. Platelets less than 100 x 109/L.

         16. WBC less than 3.0 x 109/L.

         17. ESR greater than 100 mm/h.

         18. History of alcohol or drug abuse.

         19. Participation in another clinical trial within 3 months of randomisation.

         20. Treatment with nitisinone within 3 months of randomisation

         21. Psychiatric illness or neurological disease that interferes with compliance or
             communication with health care personnel.

         22. Any other medical condition which in the opinion of the investigator makes the subject
             unsuitable for inclusion.

         23. Foreseeable inability to cooperate with given instructions or study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Ranganath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool &amp; Broadgreen University Hospitals NHS Truts</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Professor Lakshminarayan Ranganath</investigator_full_name>
    <investigator_title>Consultant in Metabolic medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

